T2 Biosystems Announces Preliminary Third Quarter 2023 Financial Results and Business UpdatesGlobeNewsWire • 10/12/23
T2 Biosystems Announces FDA 510(k) Submission to Expand the Pathogen Detection on its FDA-Cleared T2Bacteria Panel to Include Detection of Acinetobacter baumanniiGlobeNewsWire • 10/12/23
T2 Biosystems to Report Preliminary Third Quarter 2023 Financial Results and Business Updates on October 12, 2023GlobeNewsWire • 10/05/23
T2 Biosystems' stock extends losing streak despite FDA approval for anthrax and plague diagnostic testMarket Watch • 09/20/23
T2 Biosystems reaches regulatory milestone that could be a game changer, analyst saysMarket Watch • 09/20/23